Suchergebnisse - "Xu, Yingxin"

PubPharm (10)

1

Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma

enthalten in: Respiratory medicine | 2022

von Bateman, E. | Khan, A. | Xu, Y. | +8

CommentIn: Respir Med. 2022 Jan;191:106106. - PMID 32839071

2

Response to the correspondence : "Non-optimal methodology questions indirect treatment comparison of dupilumab vs other biologics in severe asthma"

enthalten in: Respiratory medicine | 2022

von Bateman, E. | Khan, A. | Xu, Y. | +8

CommentOn: Respir Med. 2022 Jan;191:105991. - PMID 35090688

3

Response to comment on : Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma (Respir. Med. 2020)

enthalten in: Respiratory medicine | 2022

von Bateman, E. | Khan, A. | Xu, Y. | +8

CommentOn: Respir Med. 2022 Jan;191:105991. - PMID 35090688

4

Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2022

von Kuznik, A. | Smare, C. | Chen, C. | +9

5

Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma

enthalten in: Journal of managed care & specialty pharmacy | 2021

von Paul, E. | Konidaris, G. | Cope, S. | +9

6

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma : A Cost-Effectiveness Analysis

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2021

von Konidaris, G. | Paul, E. | Kuznik, A. | +9

7

Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma

enthalten in: Future oncology (London, England) | 2021

von Keeping, S. | Xu, Y. | Chen, C. | +16

8

A comparative evaluation of gemtuzumab ozogamicin + daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia

enthalten in: Future oncology (London, England) | 2019

von Ashaye, A. | Khankhel, Z. | Xu, Y. | +6

9

Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia

enthalten in: Clinical therapeutics | 2017

von Sorensen, S. | Wildgust, M. | Sengupta, N. | +5

10

Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab : a systematic literature review and meta-analysis

enthalten in: Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies | 2011

von Checchia, P. | Nalysnyk, L. | Fernandes, A. | +4

1
[1]